Methods of use of anti-CD19 antibodies with reduced immunogenicity
US10072092B2 · kind B2 · utility
1Cited by
59References
17Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 12, 2015 |
| Grant date | Sep 11, 2018 |
| Priority date | — |
| Expiry date | Aug 5, 2036 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/732
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Anti-CD19 B4 antibodies with modified variable regions are disclosed. The modified anti-CD19 variable region polypeptides have alterations to one or more framework regions or complementarity determining regions of the heavy chain variable region or light chain variable region, thereby to reduce a T-cell response.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.